Processing...
Clinical Trials for Rectal Cancer
Search
Search
There are 198 active trials for advanced/metastatic rectal cancer.
Click on a trial to see more information.
198 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.
ClinicalTrials.gov ID: NCT04969315
HealthScout AI summary: This trial investigates the safety and anti-tumor activity of the investigational drug BMS-986488, alone or combined with adagrasib, cetuximab, or nivolumab, in adults with advanced malignant tumors, including specific cohorts with ccRCC, NSCLC (KRAS G12C mutation), ccOC, and CRC (KRAS G12C mutation).
ClinicalTrials.gov ID: NCT06764771
HealthScout AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express EGFR and have lost HLA-A*02 expression, including types such as CRC, NSCLC, HNSCC, TNBC, and RCC, and tests A2B395, a logic-gated Tmod™ CAR T-cell therapy designed to selectively target these tumor cells while sparing healthy cells. Participants receive a preconditioning lymphodepletion regimen followed by a single intravenous dose of A2B395.
ClinicalTrials.gov ID: NCT06682793
HealthScout AI summary: Adults with advanced, unresectable or metastatic solid tumors (including NSCLC, pancreatic, colorectal, or other types) harboring KRAS mutations (G12A, G12C, G12D, G12S, G12V) or amplification are eligible for treatment with BBO-11818, a selective oral pan-KRAS inhibitor, as monotherapy or in combination with pembrolizumab, platinum-based chemotherapy plus pemetrexed, or cetuximab.
ClinicalTrials.gov ID: NCT06917079
HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HER2-positive or hormone receptor-positive/HER2-negative breast cancer, KRAS-mutant colorectal cancer, or KRAS-mutant non-small cell lung cancer—who have received prior standard therapies, to receive BBO-10203 (a first-in-class PI3Kα:RAS interaction breaker that disrupts PI3Kα-AKT signaling) as monotherapy or in combination with trastuzumab. Key exclusions include untreated brain metastases and extensive prior ADC exposure in HER2+ breast cancer.
ClinicalTrials.gov ID: NCT06625775
HealthScout AI summary: Eligible patients are adults with locally advanced or metastatic solid tumors harboring a KRAS G12D mutation, who have progressed on or are intolerant to standard therapies and meet organ function and performance status criteria. The investigational drug TSN1611, an oral small molecule inhibitor targeting both active and inactive forms of KRAS G12D, is administered as monotherapy.
ClinicalTrials.gov ID: NCT06385925
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors or designated lymphomas (with confirmed CD161 expression) who have failed or are intolerant to standard therapies, to receive the investigational anti-CD161 monoclonal antibody IMT-009 (which blocks an inhibitory NK/T cell pathway) as monotherapy or in combination with fruquintinib.
ClinicalTrials.gov ID: NCT05565417
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring documented KRAS mutations (excluding prior G12C inhibitor-treated G12C tumors), including NSCLC, CRC, pancreatic, and other KRAS-mutated cancers, who have progressed after standard therapies. Patients receive PF-07985045, a novel oral KRAS inhibitor, as monotherapy or in combination with chemotherapy, targeted agents, or immunotherapy, depending on cohort and tumor type.
ClinicalTrials.gov ID: NCT06704724
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specific cohorts for EGFR-mutant or wild-type NSCLC, HNSCC, and metastatic CRC—to investigate AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET, given alone or in combination with standard therapies such as osimertinib or 5-FU/bevacizumab/leucovorin. Key exclusions are active ILD/pneumonitis, untreated or unstable brain metastases, active infections, or significant cardiac disease.
ClinicalTrials.gov ID: NCT05647122
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors harboring a KRASG12D mutation (including NSCLC, colorectal, and pancreatic cancers) who have progressed on standard therapy and have not previously received a direct KRAS inhibitor. The trial evaluates AZD0022, a selective oral KRAS G12D inhibitor, as monotherapy and in combination with cetuximab.
ClinicalTrials.gov ID: NCT06599502